FibroFind Accelerates Growth with Vespa Capital Investment

Vespa Capital has made a strategic investment in FibroFind, a leading pre-clinical contract research organization known for its innovative Precision Cut Tissue Slice (PCTS) platform. FibroFind's platform offers superior translational accuracy over traditional in-vivo and in-vitro models by maintaining the architecture and function of human tissues for extended periods. This novel approach supports drug developers in making informed decisions, reducing the risk of costly clinical trial failures. Originating as a spin-out from Newcastle University in 2019, FibroFind leverages academic expertise to address the growing global demand for high-quality ex-vivo testing models. The investment from Vespa Capital will help FibroFind expand the utility and application of its platform into new tissue types and therapeutic areas. The collaboration aims to enhance the company's offerings in pre-clinical testing and drug discovery. Advisors for the transaction included DLA Piper, Candesic, BDO, and others, with debt facilities from Santander.